Home spirometry to predict pulmonary exacerbations in CF: fact or fiction?

Completed

• Conditions: Cystic Fibrosis; 10024970

• Registration Number: NL-OMON31702
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

Cystic Fibrosis
Able to perform spirometry
age 4-18 years old

Exclusion Criteria

none

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Analysis of home measured FEV1 before, during and after a antibiotic treatment<br /><br>(excacerbation). A decrease of 10% or more of the FEV1 compared to the personal<br /><br>best on 3 days in a row, or a decrease wich is slowl progressive in 7 days, and<br /><br>results in a decrease of 10% or more in FEV1 is defined as a clinical relavent<br /><br>decrease in pulmonary function.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>